Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 2025 and full-year results ending Dec 31, 2025 announced Feb 26, 2026.
Ginkgo Bioworks Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 and full-year results ending Dec 31, 2025 announced Feb 26, 2026
- Actual figures in Exhibit 99.1: key metrics (revenue, margins, cash position) require reviewing attached press release
- DNA is a synthetic biology platform company; results will signal pace of commercialization and cash burn trajectory
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ginkgo Bioworks Holdings, Inc. 8-K filings
Get the next DNA 8-K as it lands
Follow DNA for push alerts, or ask the research agent what this filing means.